Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)

Janet Ford, Cristina Tassorelli, Elizabeth Leroux, Shufang Wang, David Ayer, Russell Nichols, Holland Detke

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences